Artificial intelligence is continuing to reshape healthcare, and one of its latest applications could significantly improve how women are screened for womb cancer. Several NHS hospitals are preparing to introduce an AI-powered blood test that can help determine whether patients referred for suspected womb cancer require further invasive diagnostic procedures.
The technology aims to identify patients who are at very low risk of cancer before they undergo uncomfortable examinations, potentially reducing unnecessary testing while helping doctors prioritize those who need urgent care.
How the AI Blood Test Works
The new test was developed by Leeds-based PinPoint Data Science and combines blood analysis with machine learning to estimate a patient’s likelihood of having cancer.
Rather than producing a simple positive or negative result, the system analyzes approximately 30 blood biomarkers and assigns patients to one of three risk categories: low, elevated, or high risk. Physicians can then use this risk score alongside existing referral guidelines to determine whether a patient should be monitored, undergo additional testing, or receive expedited care.
Although the current rollout focuses on womb cancer referrals, the company says the technology has also been designed for use across several other cancer pathways, including lung, gastrointestinal, and head and neck cancers.
Clinical Trial Results
The AI test was evaluated during a large clinical trial involving more than 16,000 patients referred through urgent suspected cancer pathways across Yorkshire.
Among women referred because of postmenopausal bleeding—a key symptom associated with womb cancer—roughly one in ten were ultimately diagnosed with cancer.
According to the reported findings, the AI system successfully identified over 99% of cancer cases as either elevated or high risk. For patients classified as low risk, the test demonstrated an exceptionally high negative predictive value, indicating that women placed in this category were extremely unlikely to have cancer.
These results suggest the tool could safely reduce unnecessary follow-up procedures for many patients.
Reducing Invasive Procedures
Women referred for suspected womb cancer currently undergo several diagnostic steps that can be physically uncomfortable.
The standard pathway often begins with a pelvic examination and a transvaginal ultrasound, during which an ultrasound probe is inserted into the vagina to examine the uterus and measure the thickness of the uterine lining.
If doctors remain concerned after these examinations, patients may require additional investigations such as biopsies or hysteroscopies to inspect the inside of the womb.
By identifying women with an extremely low likelihood of cancer before these procedures are performed, the AI blood test could eliminate the need for invasive testing in many cases.
PinPoint estimates that approximately one in five women currently referred for suspected womb cancer could avoid a transvaginal ultrasound if the test is widely adopted.
Hospitals Begin Adoption
Several NHS organizations are preparing to incorporate the technology into clinical practice.
Mid Yorkshire NHS Teaching Trust plans to introduce the blood test across multiple gynecological and upper gastrointestinal cancer pathways, while Leeds Teaching Hospitals NHS Trust intends to use it specifically for gynecological cancer referrals.
Clinicians believe the tool can improve patient triage by allowing lower-risk patients to remain under primary care while ensuring higher-risk individuals move more quickly into specialist diagnostic services.
Doctors also expect the test to reduce repeated GP appointments that often occur while patients wait for definitive answers.
AI Continues Expanding Across the NHS
The blood test is part of a much broader effort to integrate artificial intelligence throughout the NHS.
Hospitals are increasingly deploying AI systems to assist with infection monitoring, patient triage, medical imaging, and cancer detection. Existing projects include AI tools that analyze routine patient data to identify infection risks, digital triage assistants within the NHS App, and AI-powered chest X-ray software that supports the early detection of lung cancer.
These technologies are designed to improve clinical decision-making while helping healthcare providers manage growing patient demand more efficiently.
More Research Is Still Needed
Although the early clinical results are encouraging, researchers emphasize that additional studies will be necessary before the technology becomes a standard part of cancer care nationwide.
Future research will evaluate how the blood test influences long-term patient outcomes, referral decisions, diagnostic accuracy, and overall NHS capacity.
Cancer Research UK has described the technology as promising, noting that blood-based screening could reduce the need for invasive procedures for many women. However, the organization also stressed that further evidence is required to fully understand the test’s impact before widespread implementation.
Looking Ahead
Artificial intelligence is steadily becoming an important tool in modern medicine, particularly in cancer detection and diagnosis. Rather than replacing clinicians, systems like the PinPoint blood test provide additional data that can support faster and more informed decision-making.
If future studies continue to validate its effectiveness, AI-assisted blood testing could streamline the diagnostic process for thousands of women each year, reducing unnecessary procedures while ensuring those at greatest risk receive timely treatment. As healthcare systems continue adopting AI, innovations like this may play an increasingly important role in improving both patient experience and clinical outcomes.
Source: https://www.artificialintelligence-news.com/news/nhs-ai-blood-test-womb-cancer-checks/
